Amcenestrant is an Orally Active SERD for Breast Cancer Research
Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD) for breast cancer research.
Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD) for breast cancer research.
Estrogen receptor α (ERα) and β (ERβ) is a nuclear transcription factors involved in regulating many complex human physiological processes. Moreover, these proteins play a role in the nucleus and…